tbuckley/cabot-search huggingface dataset:
Experimental study of therapeutic activity of gemcitabine in intracranial tumors.
Authors: Aleksandr Nikolaevich Stukov, Tatiana Yurjevna Semiglazova, Larisa Valentinovna Filatova, Dilorom Hamidovna Latipova, Albina Zhabina, Vladimir Bespalov, Olesya Belyaeva, Galina Sergeevna Kireeva, Sofia Vershinina, Vladimir Moiseyenko, Viacheslav Chubenko
Journal: Journal of Clinical Oncology (2015)

e22180 Background: Gemcitabine is known to exert a therapeutic effect on brain tumors despite the limited permeability of the blood-brain barrier (BBB). Experimental studies to explore the mechanism of this phenomenon are advisable. Methods: The study was carried out in BALB/c mices with intracranially transplanted Ehrlich tumor. Results: Single intraperitoneal (i.p.) injection of gemcitabine 25 mg/kg provided increase in median survival of mice with intracranially transplanted Ehrlich carcinoma by 41-89% (р < 0,001). In this experimental model i.p. administration of gemcitabine (permeability of the BBB of less than 10%), carmustine (good permeability of the BBB), cyclophosphamide (poor permeability of the BBB) and cisplatin (doesn’t penetrate through the BBB) increased median survival of mice by 88% (р < 0,001), 59% (р = 0,001), 35% (р = 0,005) and 18% (р = 0,302) respectively. Conclusions: Considering strong correlation between antitumor activity of the drugs (carmustine, cyclophosphamide and cisplatin) and their permeability of the BBB, efficacy of gemcitabine in intracranial tumors could be due to its wide range of therapeutic doses. On the other hand poor permeabililty of gemcitabine of the BBB makes it a promising antitumor drug for intrathecal chemotherapy.
FRI-186-Entecavir plus pegylated interferon alfa-2a and sequential HBV vaccination increases the chance of HBsAg-seroclearance: Results from a randomized controlled E+VIP trial
Authors: Jeonghoon Lee, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Journal: Journal of Hepatology (2019)
Synchronous and metachronous second malignancies in multiple myeloma (MM).
Authors: Jennifer A Wilkinson, Mark A Fiala, Ravi Vij, Joseph Finney, Keith Stockerl-Goldstein, Tanya Marya Wildes
Journal: Journal of Clinical Oncology (2015)

e19535 Background: MM is an incurable plasma cell cancer whose incidence increases with age. As treatment for MM has advanced so has recognition of second malignancies (SMs). Our goal was to identify the most common types of SMs by timing of diagnosis and assess the influence of synchronous and SMs on overall survival in patients with MM. Methods: We identified all patients diagnosed with MM at Washington University from 2000-2013 from the Barnes Jewish Hospital Oncology Data Services Database. Patients not meeting CRAB criteria for MM were excluded. Medical records were reviewed for evidence of additional malignancies. SMs were categorized as AMM (antecedent metachronous) if diagnosed >3 months before MM, SSM (synchronous) if ± 3 months of MM diagnosis, or PMM (post metachronous) if >3 months after MM. Non-melanoma skin cancers were excluded. Overall survival (OS) was examined with Kaplan-Meier curves and the log-rank test. Results: In total 1,096 patients were analyzed. The median age at diagnosis was 60 (range 25-94), 55% were male; 74.7% were white race, 23% black and 2.3% other. Among the 738 who had ISS staging available, 29.4% had stage I, 31.6% stage II and 39.0% stage III. 124 patients (11.3%) had a SM (of which 63% were AMM; 11.2% SSM; 26.4% PMM); 18 (1.6%) had a 3rd malignancy; 4 (0.3%) had a 4thmalignancy. Patients with a SM were significantly older than patients without (mean 64.3 years vs 59.3, p<0.0001). Table 1 demonstrates the most common histologies of SMs by timing of presentation. Controlling for age and ISS, median OS did not differ between patients who did or did not have a SM (p=0.52). Conclusions: Over 10% of patients with MM had a second malignancy, though SMs did not impact overall survival. The most common AMMs were as expected based on prevalent malignancies, while 24% of PMMs were AML/MDS. Future study will investigate the relationship between MM treatment and PMMs. Types of SMs and OS. AMM (N=79) SSM (N=14) PMM (N=33) No SM Most common SMs Breast (16) Prostate (16) Colon (8) Lung (5) Prostate (4) Breast (2) Kidney (2) CLL (2) MDS/AML (8) Breast (5) Prostate (4) Kidney (4) Not applicable OS (median (mos), 95% CIs) 46.5 (26.2-66.9) 66.3 (not calculable) 66.8 (20.6-112.9) 56.0 (49.6-62.3)
Specific contribution of mannose-binding lectin murine isoforms to brain ischemia/reperfusion injury
Authors: Laura Neglia, Marco Oggioni, Domenico Mercurio, Maria-Grazia De Simoni, Stefano Fumagalli
Journal: Cellular and Molecular Immunology (2019)

Mannose-binding lectin (MBL), an initiator of the lectin pathway (LP) of complement activation, is detrimental in ischemic stroke, as shown in clinical studies and rodent models. Whereas humans have one functional MBL protein, rodents have two isoforms, MBL-A and MBL-C, whose functions relative to that of human MBL are unknown. To permit the clinical translation of preclinical data, we aimed to define the specific contributions of MBL-A and MBL-C to brain ischemia. We subjected mice with double (MBL-/-) or single (MBL-A-/- or MBL-C-/-) MBL isoform depletion to transient middle cerebral artery occlusion (tMCAo). MBL-/- mice had fewer neurological deficits and smaller ischemic lesions than WT mice. MBL-A-/- mice had smaller lesions than WT mice and exhibited no significant behavioral defects, whereas MBL-C-/- mice did not differ from WT mice. The induction of Mbl1 and Mbl2 (the MBL-A and MBL-C genes) expression 48 h after tMCAo was similar across genotypes. The time course of Mbl1 and Mbl2 expression in WT ischemic mice showed that Mbl1 activation occurred earlier (24 h) than Mbl2 activation (48 h). The plasma levels of MBL-A and MBL-C in MBL-C-/- and MBL-A-/- mice, respectively, were similar to those in WT mice both at baseline and at 48 h after tMCAo. At 48 h, MBL-A-/- ischemic mice showed higher MBL-C levels in the brain than WT mice. WT and MBL-C-/- ischemic mice had higher LP activity in plasma and, accordingly, higher levels of C3 deposition in the brain than MBL-A-/- and MBL-/- mice. In conclusion, mice with depletion of both MBL isoforms exhibited strong protection from ischemia/reperfusion injury. MBL-A was the main contributor to injury, likely owing to its earlier activation after ischemia and more efficient activation of the complement system than MBL-C.
THU-137-DAA therapy in women of child bearing age: Accidental conception during therapy and pregnancy outcome
Authors: Manal Hamdy El-Sayed, Wafaa Elakel, Aisha Elsharkawy, Rasha Eletreby, Kadry Elsaees, Yehia Elshazly, Magdi El-Serafy, Wahid Doss
Journal: Journal of Hepatology (2019)
SAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites
Authors: Florence Wong, Rajender Reddy, Puneeta Tandon, Jacqueline O’leary, Guadalupe Garcia-Tsao, Jennifer Lai, Hugo E. Vargas, Scott Biggins, Benedict Maliakkal, Michael Fallon, Ram Subramanian, Paul J. Thuluvath, Patrick S. Kamath, Leroy Thacker, Jasmohan S Bajaj
Journal: Journal of Hepatology (2019)
FRI-435-Progression to cirrhosis is not infrequent in patients with Wilson’s disease despite treatment
Authors: Zoe Mariño, Anna Pocurull, Mercedes Vergara Gómez, Helena Masnou, Susana Coll, Gilberto Silva-Junior, Debora Angrisani, Virginia Hernandez-Gea, Celia Badenas, Xavier Forns
Journal: Journal of Hepatology (2019)
FRI-494-Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis
Authors: Markus Peck-Radosavljevic, Han Chu Lee, Masatoshi Kudo, Keiko Nakajima, Inga Bayh, Ann-Lii Cheng, Jean-Luc Raoul
Journal: Journal of Hepatology (2019)
PS-142-Analysis of sorafenib-regorafenib sequential therapy in patients with advanced hepatocellular carcinoma using baseline date of sorafenib
Authors: Sae Yumita, Sadahisa Ogasawara, Yoshihiko Ooka, Kazufumi Kobayashi, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Takahiro Maeda, Yuko Kusakabe, Soichiro Kiyono, Masato Nakamura, Tomoko Saito, Eiichiro Suzuki, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato
Journal: Journal of Hepatology (2019)
FRI-176-Orally administered TQ-A3334 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics single and multiple ascending doses in healthy Chinese subjects
Authors: Yue Hu, Hong Zhang, Min Wu, Dandan Huo, Hong Chen, Xiaojiao Li, Zhongnan Xu, Yanhua Ding, Junqi Niu
Journal: Journal of Hepatology (2019)
SAT-224-Design and validation of a risk prediction model for hepatocellular carcinoma development after sustained virological response in chronic hepatitis C patients
Authors: Ho Soo Chun, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Cheol-Hyung Lee, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeonghoon Lee
Journal: Journal of Hepatology (2019)
Similar characteristics of nontuberculous mycobacterial pulmonary disease in men and women
Authors: Michael R. Holt, Shannon H. Kasperbauer, Tilman L. Koelsch, Charles L. Daley
Journal: European Respiratory Journal (2019)

<b>In a retrospective study of patients with nontuberculous mycobacterial pulmonary disease in the absence of clinically apparent risk factors, men and women shared phenotypic and other characteristics but lesser disease severity was observed in men</b>http://bit.ly/2YAV7QB
Abstract 17099: Mortality From Heart Failure and Dementia in the United States: Centers for Disease Control (CDC) WONDER 1999 to 2015
Authors: Jacqueline T Vuong, Sophia Jacob, Kevin Alexander, Avinainder Singh, Ronglih Liao, Akshay Desai, Sharmila Dorbala
Journal: Circulation (2017)

Introduction: Dementia complicates the management of heart failure and may be associated with higher risk for death and readmission. Dementia and heart failure also share pathophysiologic risk fact...
Abstract 18213: Advanced Glycation End-Product Inhibition With Alagebrium Slows Age-Related Large Vessel Arterial Stiffening in Healthy Elderly Humans
Authors: Shigeki Shibata, Naoki Fujimoto, Jeffrey L Hastings, Paul S Bhella, Graeme Carrick-Ranson, Tom Sarma, Yoshiyuki Okada, Dean Palmer, Kara Boyd, Sheryl Livingston, Benjamin D Levine
Journal: Circulation (2013)

Background: Lifelong exercise training maintains youthful compliance of the central arteries, while even prolonged (1 yr) and intense training started later in life failed to reverse age-related central arterial stiffening, possibly because of accumulation of irreversible advanced glycation end-products (AGE). Alagebrium breaks AGE crosslinks and improves central arterial compliance in animals. However, little is known how Alagebrium would affect central arterial compliance in previously sedentary elderly humans. Moreover, it is unclear whether a strategy of exercise training combined with Alagebrium would improve central arterial compliance. Methods: Sixty two healthy elderly subjects were randomized into 4 groups: a) Sedentary+placebo; b) Sedentary+Alagebrium (200mg/day); c) Exercise+placebo; and d) Exercise+Alagebrium. Fifty seven/62 subjects (67±6 yrs; 37f/20m) completed 1 yr of intervention followed by repeat measurements. Arterial compliance were evaluated with Modelflow generated aortic age (A-age), central and peripheral pulse wave velocity (PWVs), carotid artery, and ascending and descending aorta beta stiffness indices (Beta indices), and augmentation index (AI). A-age was calculated from the finger blood pressure waveform (BMEYE) and stroke volume (Thermodilution) ( Shibata 2010 ). Central blood pressure, PWVs and AI were measured with applantation of tonometry (SphygmoCor). Aortic and carotid arterial geometries were assessed with MRI and ultrasound, respectively. Results: A-age increased less over the 1 yr intervention in the Alagebrium groups (Medication х Time effect p=0.066). Also, AI increased significantly less in the Alagebrium groups (Medication х Time effect p=0.034). However, exercise training did not impact on any of these indices. There were no significant differences in either Beta indices or PWVs. No subject developed aortic dilatation or had any CV complications (safety endpoint). Conclusion: Breaking of AGE cross links with Alagebrium was safe, and slowed but did not reverse age related large vessel arterial stiffening in elderly humans without an additive effect of exercise training. The absence of concordant changes in all indices suggests that these effects were modest.
TCTAP A-078 Short- and Long-term Outcome of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in Patients with Mild Left Ventricular Hypertrophy: A Propensity Score Matching Analysis
Authors: Josef Veselka, Lothar Faber, Max Liebregts, Robert Cooper, Maksim Kashtanov, Jaroslav Januska, Maciej Dabrowski, Eva Hansvenclova, Peter Riis Hansen, Hubert Segewiss, Dieter Horstkotte, Henning Bundgaard, Rodney Hilton Stables, Jurriën Ten Berg, Morten Kvistholm Jensen
Journal: Journal of the American College of Cardiology (2019)
Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells
Authors: Wei Bu, M. Gordon Joyce, Hanh Nguyen, Dalton V. Banh, Fiona Aguilar, Zeshan Tariq, Moh Lan Yap, Yusuke Tsujimura, Rebecca A. Gillespie, Yaroslav Tsybovsky, Sarah F. Andrews, Sandeep R. Narpala, Adrian B. McDermott, Michael G. Rossmann, Yasuhiro Yasutomi, Gary J. Nabel, Masaru Kanekiyo, Jeffrey I. Cohen
Journal: Immunity (2019)
Validation of five patient‐reported outcomes for atopic dermatitis severity in adults
Authors: J.I. Silverberg, D.J. Margolis, M. Boguniewicz, L. Fonacier, M.H. Grayson, P.Y. Ong, Z.C. Fuxench, E.L. Simpson
Journal: British Journal of Dermatology (2019)

Structured patient‐reported outcomes of atopic dermatitis (AD) severity are not standardized in clinical practice. To determine the construct validity, internal consistency, cross‐cultural validity and floor or ceiling effects of multiple AD severity assessments. This is a cross‐sectional, population‐based study of 2893 adults, including 602 adults who met a modified set of U.K. diagnostic criteria for AD. AD severity was assessed using self‐reported global AD severity, Patient‐Oriented Eczema Measure (POEM), Patient‐Oriented Scoring Atopic Dermatitis (PO‐SCORAD) and its objective and subjective components, and numerical rating scale (NRS)‐itch. Quality of life was assessed using Short‐Form (SF)‐12 mental and physical health scores, Short‐Form Six Dimensions (SF‐6D) health utility scores and Dermatology Life Quality Index (DLQI). Mental health was assessed with the Hospital Anxiety and Depression Scale (HADS). PO‐SCORAD, PO‐SCORAD objective and subjective subscores, NRS‐itch and POEM all had moderate‐to‐strong correlations with each other and DLQI, fair‐to‐moderate correlations with HADS‐anxiety and HADS‐depression, and inverse correlations with SF‐12 mental component score and SF‐6D (Pearson correlations, P < 0·001). All scores showed good criterion validity as judged by anova and receiver operator characteristics. PO‐SCORAD, PO‐SCORAD objective subscore and POEM had similarly good internal consistency (Cronbach's alpha = 0·84, 0·82 and 0·86); the PO‐SCORAD subjective subscore was less internally consistent (alpha = 0·57). All scores showed potentially poor cross‐cultural validity as demonstrated by uniform and nonuniform differential item functioning by age, sex and/or race/ethnicity for multiple items. There were floor effects for POEM, but not for the other assessments. PO‐SCORAD, PO‐SCORAD objective and subjective subscores, NRS‐itch and POEM appear to be valid for assessing AD severity in clinical practice. What's already known about this topic? Few studies have demonstrated the validity of the atopic dermatitis severity assessments Patient‐Oriented Scoring Atopic Dermatitis (PO‐SCORAD), PO‐SCORAD subscores, numerical rating scale (NRS)‐itch and Patient‐Oriented Eczema Measure (POEM). What does this study add? This study demonstrates that PO‐SCORAD, PO‐SCORAD subscores, NRS‐itch and POEM all had good construct validity in the assessment of atopic dermatitis severity in adults. Only POEM demonstrated floor effects. What are the clinical implications of this work? PO‐SCORAD, PO‐SCORAD subscores, NRS‐itch and POEM all appear to have sufficient validity to be used as assessments of atopic dermatitis severity in clinical practice.
Adaptive NK cells in people exposed to <i>Plasmodium falciparum</i> correlate with protection from malaria
Authors: Geoffrey T. Hart, Tuan M. Tran, Jakob Theorell, Heinrich Schlums, Gunjan Arora, Sumati Rajagopalan, A.D. Jules Sangala, Kerry J. Welsh, Boubacar Traore, Susan K. Pierce, Peter D. Crompton, Yenan T. Bryceson, Eric O. Long
Journal: The Journal of Experimental Medicine (2019)

How antibodies naturally acquired during Plasmodium falciparum infection provide clinical immunity to blood-stage malaria is unclear. We studied the function of natural killer (NK) cells in people living in a malaria-endemic region of Mali. Multi-parameter flow cytometry revealed a high proportion of adaptive NK cells, which are defined by the loss of transcription factor PLZF and Fc receptor γ-chain. Adaptive NK cells dominated antibody-dependent cellular cytotoxicity responses, and their frequency within total NK cells correlated with lower parasitemia and resistance to malaria. P. falciparum–infected RBCs induced NK cell degranulation after addition of plasma from malaria-resistant individuals. Malaria-susceptible subjects with the largest increase in PLZF-negative NK cells during the transmission season had improved odds of resistance during the subsequent season. Thus, antibody-dependent lysis of P. falciparum–infected RBCs by NK cells may be a mechanism of acquired immunity to malaria. Consideration of antibody-dependent NK cell responses to P. falciparum antigens is therefore warranted in the design of malaria vaccines.
THU-291-Is non-alcoholic fatty liver disease a risk factor for chronic kidney disease?
Authors: Takemi Akahane, Tadashi Namisaki, Kei Moriya, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato, Shinya Sato, Yasuhiko Sawada, Keisuke Nakanishi, Masanori Furukawa, Yukihisa Fujinaga, Yuki Tsuji, Hitoshi YOSHIJI
Journal: Journal of Hepatology (2019)
SAT-231-Impact of the HCV cure with DAAs in the use of concomitant medication and the serum lipid profile: Follow-up data one year after the SVR12
Authors: Elena González-Colominas, Marc Batlle, Inés Monge-Escartín, Xavier Duran, Ana Viu, Marta de Antonio, Santiago Grau, Xavier Bessa, Jose A. Carrión
Journal: Journal of Hepatology (2019)
TCTAP C-168 IVUS Guiding Intentional Subintimal Tracking Using 100g Tip-load Japanese Stiff Wire for the Undilated SFA-CTO Lesion
Authors: Takafumi Fuwa, Naoto Inoue, Yuki Endo, Tadashi Yamagishi, Yutaka Koyama
Journal: Journal of the American College of Cardiology (2019)
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
Authors: Utpal K Mukhopadhyay, Chetan C Oturkar, Christina Adams, Nadi Wickramasekera, Sanjay Bansal, Rajesh Medisetty, Austin Miller, Wendy M Swetzig, Laxmi Silwal-Pandit, Anne-Lise Børresen-Dale, Chad J Creighton, Jun Hyoung Park, Santhi D Konduri, Alka Mukhopadhyay, Alexander Caradori, Angela Omilian, Wiam Bshara, Benny Abraham Kaipparettu, Gokul M Das
Journal: JNCI Journal of the National Cancer Institute (2019)

Abstract Background Anti-tumorigenic vs pro-tumorigenic roles of estrogen receptor-beta (ESR2) in breast cancer remain unsettled. We investigated the potential of TP53 status to be a determinant of the bi-faceted role of ESR2 and associated therapeutic implications for triple negative breast cancer (TNBC). Methods ESR2-TP53 interaction was analyzed with multiple assays including the in situ proximity ligation assay. Transcriptional effects on TP53-target genes and cell proliferation in response to knocking down or overexpressing ESR2 were determined. Patient survival according to ESR2 expression levels and TP53 mutation status was analyzed in the basal-like TNBC subgroup in the Molecular Taxonomy of Breast Cancer International Consortium (n = 308) and Roswell Park Comprehensive Cancer Center (n = 46) patient cohorts by univariate Cox regression and log-rank test. All statistical tests are two-sided. Results ESR2 interaction with wild-type and mutant TP53 caused pro-proliferative and anti-proliferative effects, respectively. Depleting ESR2 in cells expressing wild-type TP53 resulted in increased expression of TP53-target genes CDKN1A (control group mean [SD] = 1 [0.13] vs ESR2 depletion group mean [SD] = 2.08 [0.24], P = .003) and BBC3 (control group mean [SD] = 1 [0.06] vs ESR2 depleted group mean [SD] = 1.92 [0.25], P = .003); however, expression of CDKN1A (control group mean [SD] = 1 [0.21] vs ESR2 depleted group mean [SD] = 0.56 [0.12], P = .02) and BBC3 (control group mean [SD] = 1 [0.03] vs ESR2 depleted group mean [SD] = 0.55 [0.09], P = .008) was decreased in cells expressing mutant TP53. Overexpressing ESR2 had opposite effects. Tamoxifen increased ESR2-mutant TP53 interaction, leading to reactivation of TP73 and apoptosis. High levels of ESR2 expression in mutant TP53-expressing basal-like tumors is associated with better prognosis (Molecular Taxonomy of Breast Cancer International Consortium cohort: log-rank P = .001; hazard ratio = 0.26, 95% confidence interval = 0.08 to 0.84, univariate Cox P = .02). Conclusions TP53 status is a determinant of the functional duality of ESR2. Our study suggests that ESR2-mutant TP53 combination prognosticates survival in TNBC revealing a novel strategy to stratify TNBC for therapeutic intervention potentially by repurposing tamoxifen.
Stereotactic ablative radiotherapy (SABR) as re-irradiation for an isolated infield lymph node recurrence.
Authors: Neal Bhatt, Neal E Dunlap, Xiaoyong Wu, Shesh Rai, Anthony E. Dragun
Journal: Journal of Clinical Oncology (2015)

11083 Background: Oligometastatic disease presents a unique opportunity for local therapy to provide cure. The aims of this study were to evaluate the safety and efficacy of stereotactic ablative radiotherapy (SABR) as a local treatment for isolated lymph node recurrence in a previously irradiated field. Methods: Between January of 2010 and September of 2014, 33 patients were reviewed from a prospectively collected database. Eighteen of 33 patients had biopsy proven recurrence and all patients were shown to have isolated metastases by positron emission tomography (PET)–CT. All patients had previously received full dose radiation treatment with radical intent, with a median total dose of 56 Gy (range, 46-74) delivered with standard fractionation. The median duration from initial radiotherapy to lymph node recurrence was 11.2 months. The overall survival (OS), local control (LC) rate, and disease progression–free survival (DPFS) rate were calculated according to the Kaplan-Meier method. Comparison between prognosis groups and toxicities was performed using log-rank analysis. Results: All patients completed the prescribed treatment. The median tumor dose and fractions administered was 40 Gy (range, 24-50) in 5 fractions. The median follow-up was 10 months (range, 1-33). Three grade 3 toxicities were observed including radiation pneumonitis, displaced fracture, and pelvic pain. No Grade 4 toxicities were recorded. Results at last follow up demonstrated a local control of 90.9%, Regional control (adjacent nodal station) of 66.7%, and distant failure of 27.3%. The median time to any failure was 4.5 months with a 1 year OS of 45.5%, and DPFS 62.3%. Conclusions: SABR salvage to macroscopic nodal recurrences provides local control and long-term disease-free survival in carefully selected patients with a low incidence of toxicities. Further investigation is warranted to identify those patients who benefit most from this treatment modality.